Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will hold its third-quarter earnings conference call on Nov. 1, 2022, at 4:30 p.m. ET. Earnings will be released prior to market opening that day. Key executives, including CEO Paul J. Diaz and CFO R. Bryan Riggsbee, will discuss business performance for the period ending Sept. 30, 2022. Domestic callers can reach the event at 1-800-954-0689, while international callers may dial 1-212-231-2937. A live webcast will be available at www.myriad.com. Myriad specializes in genetic tests to improve patient care and reduce healthcare costs.

SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third-quarter earnings conference call on Tuesday, Nov. 1, 2022 at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day prior to the market opening.

During the call, Paul J. Diaz, president and chief executive officer, R. Bryan Riggsbee, chief financial officer, and Nicole Lambert, chief operating officer, will provide a financial overview and business update of Myriad’s performance for the period ending Sept. 30, 2022.

The dial-in number for domestic callers is 1-800-954-0689. International callers may dial 1-212-231-2937. All callers will be asked to reference reservation number 22021060. An archived replay of the call will be available for seven days by dialing 1-800-954-0689 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Media Contact: Megan Manzari (385) 318-3718 Megan.Manzari@myriad.com

Investor Contact: Matt Scalo (801) 584-3532 Matt.Scalo@myriad.com

 

FAQ

When will Myriad Genetics release its third-quarter earnings?

Myriad Genetics will release its third-quarter earnings on Nov. 1, 2022.

What is the date and time for Myriad Genetics' earnings conference call?

The earnings conference call for Myriad Genetics is scheduled for Nov. 1, 2022, at 4:30 p.m. ET.

Who will present during the Myriad Genetics earnings call?

Paul J. Diaz, CEO, R. Bryan Riggsbee, CFO, and Nicole Lambert, COO, will present during the call.

How can I access the Myriad Genetics earnings call?

You can access the call by dialing 1-800-954-0689 for domestic calls or 1-212-231-2937 for international calls, or by visiting www.myriad.com for the live webcast.